<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919955</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000666</org_study_id>
    <nct_id>NCT03919955</nct_id>
  </id_info>
  <brief_title>A Novel Pharmacological Therapy for Obstructive Sleep Apnea</brief_title>
  <official_title>A Novel Pharmacological Therapy for Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains&#xD;
      elusive. Here the investigators study the effect on sleep apnea severity of a combination of&#xD;
      pharmacological agents (atomoxetine and oxybutynin, &quot;AtoOxy&quot;) over a 1 month period of time.&#xD;
      The current study will answer the following questions: Does ongoing, repeated-dose&#xD;
      administration of atomoxetine-plus-oxybutynin (referred to as &quot;AtoOxy&quot;) improve OSA severity,&#xD;
      and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic&#xD;
      subgroup of patients preferentially benefit from this intervention?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1 - Effect of AtoOxy on sleep apnea severity. In a randomized controlled double-blind&#xD;
      crossover study, 48 patients with moderate-to-severe OSA will take&#xD;
      atomoxetine-plus-oxybutynin (&quot;AtoOxy&quot;) versus placebo nightly for 1 month, with a 2-week&#xD;
      washout in between. The investigators will test the hypothesis that AtoOxy reduces the&#xD;
      Apnea-hypopnea index (primary outcome measure), and improves the following secondary&#xD;
      outcomes:&#xD;
&#xD;
        -  Nocturnal oxygenation, per &quot;hypoxic burden of sleep apnea&quot;&#xD;
&#xD;
        -  Frequency of arousals from sleep (Arousal index)&#xD;
&#xD;
        -  Self-reported sleepiness (Epworth Sleepiness Scale)&#xD;
&#xD;
        -  Disease-specific quality of life (Functional Outcomes of Sleep Questionnaire, Short&#xD;
           Form).&#xD;
&#xD;
        -  Disease-specific quality of life (Sleep Apnea Quality of Life Index, Short Form)&#xD;
&#xD;
      Additional pre-specified exploratory outcome measures will be assessed, including Visual&#xD;
      Analog Scales (Sleep Quality, Treatment Satisfaction) and additional polysomnographic&#xD;
      measures of sleep (Stage 1 sleep, %total sleep time). Adherence and adverse events will also&#xD;
      be carefully monitored to assess repeated-dose tolerance of the intervention.&#xD;
&#xD;
      Aim 2 - Determine which patient phenotypes respond best to AtoOxy. Patients will also take&#xD;
      part in an additional night before initiating study medication to measure the key mechanisms&#xD;
      causing OSA. The investigators will prospectively test the hypothesis that greater pharyngeal&#xD;
      collapsibility determines a reduced response to therapy. They will also separately test the&#xD;
      hypotheses that a reduced muscle responsiveness, reduced baseline muscle activation, a higher&#xD;
      arousal threshold, and a lower loop gain will facilitate a greater response to therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-hypopnea index [AHI]</measure>
    <time_frame>one month</time_frame>
    <description>Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxic Burden</measure>
    <time_frame>one month</time_frame>
    <description>Desaturation area under curve Ã— event frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal index</measure>
    <time_frame>one month</time_frame>
    <description>Scored EEG arousals per hour (&gt;3 s), % change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>one month</time_frame>
    <description>Self-reported sleepiness on scale of 0-24, higher being more sleepy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcomes of Sleep Questionnaire, Short Form</measure>
    <time_frame>one month</time_frame>
    <description>Disease-specific quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Apnea Quality of Life Index, Short Form</measure>
    <time_frame>one month</time_frame>
    <description>Disease-specific quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Atomoxetine and Oxybutynin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>Atomoxetine 80 mg, per mouth, before bed</description>
    <arm_group_label>Atomoxetine and Oxybutynin</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>Oxybutynin 5 mg, per mouth, before bed</description>
    <arm_group_label>Atomoxetine and Oxybutynin</arm_group_label>
    <other_name>Ditropan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, per mouth, before bed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ages 21-70 years&#xD;
&#xD;
          -  Diagnosed OSA or clinically-suspected OSA&#xD;
&#xD;
          -  Not using CPAP (&gt;1 month).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any uncontrolled medical condition&#xD;
&#xD;
          -  Current use of the medications under investigation&#xD;
&#xD;
          -  Use of medications expected to stimulate or depress respiration (including opioids,&#xD;
             barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).&#xD;
&#xD;
          -  Current use of hypnotic medications (trazodone, eszopiclone, benzodiazepines).&#xD;
&#xD;
          -  Current use of SNRIs/SSRIs or anticholinergic medications.&#xD;
&#xD;
          -  Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease&#xD;
             or other major neurological disorder, heart failure (also below), or any other&#xD;
             unstable major medical condition.&#xD;
&#xD;
          -  Respiratory disorders other than sleep disordered breathing:&#xD;
&#xD;
        chronic hypoventilation/hypoxemia (awake SaO2 &lt; 92% by oximetry) due to chronic obstructive&#xD;
        pulmonary disease or other respiratory conditions.&#xD;
&#xD;
          -  Other sleep disorders: periodic limb movements (periodic limb movement arousal index &gt;&#xD;
             10/hr), narcolepsy, or parasomnias.&#xD;
&#xD;
          -  Contraindications for atomoxetine and oxybutynin, including:&#xD;
&#xD;
               -  hypersensitivity to study drugs (angioedema or urticaria)&#xD;
&#xD;
               -  pheochromocytoma&#xD;
&#xD;
               -  use of monoamine oxidase inhibitors&#xD;
&#xD;
               -  benign prostatic hypertrophy, urinary retention&#xD;
&#xD;
               -  untreated narrow angle glaucoma&#xD;
&#xD;
               -  bipolar disorder, mania, psychosis&#xD;
&#xD;
               -  history of major depressive disorder (age&lt;24).&#xD;
&#xD;
               -  history of attempted suicide or suicidal ideation within one year prior to&#xD;
                  screening&#xD;
&#xD;
               -  clinically significant constipation, gastric retention&#xD;
&#xD;
               -  pre-existing seizure disorders&#xD;
&#xD;
               -  clinically-significant kidney disorders (eGFR&lt;60 ml/min/1.73m2)&#xD;
&#xD;
               -  clinically-significant liver disorders&#xD;
&#xD;
               -  clinically-significant cardiovascular conditions&#xD;
&#xD;
               -  severe hypertension (SBP&gt;180 mmHg or DBP&gt;110 mmHg measured at baseline)&#xD;
&#xD;
               -  cardiomyopathy (LVEF&lt;50%) or heart failure&#xD;
&#xD;
               -  advanced atherosclerosis&#xD;
&#xD;
               -  history of cerebrovascular events&#xD;
&#xD;
               -  history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation&#xD;
&#xD;
               -  other serious cardiac conditions that would raise the consequences of an increase&#xD;
                  in blood pressure or heart rate&#xD;
&#xD;
               -  myasthenia gravis&#xD;
&#xD;
               -  pregnancy/breast-feeding&#xD;
&#xD;
          -  Allergy to lidocaine (Aim 2 only)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A Sands, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott A Sands, PhD</last_name>
    <phone>6172780911</phone>
    <email>sasands@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hess</last_name>
      <phone>617-732-8976</phone>
      <email>lhess1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Scott Aaron Sands</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD collected during the study, after deidentification, will be available immediately after publication to researchers who provide a methodologically sound proposal for any purpose.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately after publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>1-page proposals should be directed to Dr. Scott Sands (sasands@bwh.harvard.edu). To gain access, requestors will be asked to sign a data use agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

